#United States #Coral Gables #Capsida Biotherapeutics #gene therapy #STXBP1

Capsida Biotherapeutics to Present at HealthCONx Conference

Capsida Biotherapeutics, an innovative name in the realm of next-generation gene therapy, recently announced its participation in the 7th Annual Evercore HealthCONx Conference. This event, scheduled from December 3-5, 2024, in Coral Gables, Florida, serves as a platform for Capsida to discuss its advancements in treatment development for various neurological disorders.

The company's management team is particularly focused on showcasing their progress on IV-administered gene therapies. These therapies leverage proprietary engineered capsids that allow for high transduction rates in neurons while minimizing exposure to non-target organs such as the liver. This pioneering approach aims to enhance the safety and effectiveness of gene therapies, which is critical in treating notoriously difficult diseases.

Among their leading programs is CAP-002, designed to address STXBP1 developmental and epileptic encephalopathy, and CAP-003, which targets Parkinson's disease associated with GBA mutations. Both initiatives are on course for IND (Investigational New Drug) filings in the first half of 2025. A third initiative, CAP-004, is currently undergoing IND-enabling studies focusing on Friedreich's ataxia, a condition that affects coordination and muscle control.

Peter Anastasiou, CEO of Capsida, is set to participate in a fireside chat on December 4, 2024, at 12:55 PM ET, providing insights into the company's vision and future directions. In addition to the main presentation, the Capsida team will engage in one-on-one meetings with investors to discuss potential collaboration and opportunities in the evolving field of gene therapy.

As a fully integrated gene therapy firm, Capsida boasts a pipeline that includes groundbreaking solutions for both rare and common diseases affecting individuals across all age groups. Their commitment to developing disease-modifying and potentially curative treatments is evident in their robust pipeline: from the promising STXBP1 treatment to advanced therapies for Parkinson's disease and Friedreich's ataxia.

Capsida is not working in isolation; the company has established valuable partnerships with industry titans like AbbVie, Lilly, and CRISPR Therapeutics. These alliances underscore the collaborative spirit necessary for advancing complex biotechnological solutions. Capsida was founded in 2019 by key investors Versant Ventures and Westlake Village BioPartners. The company originated from pioneering research conducted in the laboratory of Dr. Viviana Gradinaru, a highly respected neuroscience professor at Caltech.

For those interested in following Capsida's journey or seeking more information about their latest developments, updates can be found on their official website at www.capsida.com.

In conclusion, Capsida Biotherapeutics is making significant strides in the gene therapy sector, aiming to bring transformative treatments to market. Their participation in the HealthCONx Conference is a testament to their ongoing commitment to innovation and the potential to change lives affected by devastating neurological diseases.